GRFSGrifols SA

Nasdaq grifols.com


$ 8.26 $ -0.59 (-6.67 %)    

Friday, 12-Jul-2024 15:59:50 EDT
QQQ $ 494.79 $ 2.89 (0.59 %)
DIA $ 400.37 $ 2.69 (0.68 %)
SPY $ 559.91 $ 3.51 (0.63 %)
TLT $ 93.88 $ 0.40 (0.43 %)
GLD $ 223.10 $ -0.14 (-0.06 %)
$ 8.26
$ 8.91
$ 8.24 x 800
$ 0.00 x 0
$ 8.25 - $ 8.92
$ 5.30 - $ 12.15
3,707,639
na
5.68B
$ 0.84
$ 17.00
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 grifols-board-votes-to-grant-brookfield-access-to-information-for-potential-takeover-bid-establishes-independent-committee-to-monitor-transaction-progress-and-present-proposals-to-board

- Reuters 

 beleaguered-spanish-drug-firm-grifols-stock-jumps-on-monday---heres-why

Grifols reveals Brookfield Capital's preliminary discussions with major shareholders about a potential joint bid to delist ...

Core News & Articles
Market-Moving News for July 8th
07/08/2024 12:38:38

GRFS: 31% | Brookfield Confirms It Held Exploratory Discussions With Certain Reference Shareholders Of Co In Relation To A Pote...

 brookfield-confirms-it-held-exploratory-discussions-with-certain-reference-shareholders-of-co-in-relation-to-a-potential-joint-offer-for-grifols-shares-to-delist-them

In relation to certain rumors appearing in the media about a potential transaction involving Grifols, S.A. ("Grifols" o...

 grifolss-subsidiary-biotest-forecasts-approximately-1b-in-revenue-from-sales-in-the-us-of-its-intravenous-immunoglobulin-yimmugo-during-the-next-seven-years-following-recent-fda-approval-to-treat-primary-immunodeficiencies

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in f...

 grifols-says-at-end-june-2024-considering-sraas-proceeds-leverage-ratio-is-expected-to-reach-54x-vs-68x-in-march-2024-fcf-in-q2-2024-expected-to-be-positive-contributing-to-reach-5-million-fy24-guidance-which-includes-480-million-of-extraordinary-items-by-end-june-liquidity-will-stand-at-more-than-24-billion-including-sraas-proceeds-is-completely-separate-entity-from-scranton-and-none-of-scrantons-liabilities-are-consolidated-at-cos-group

- Reuters

 grifols-says-16-billion-net-cash-proceeds-from-sale-of-20-equity-stake-in-shanghai-raas-are-currently-deposited-in-cos-bank-account-proceeds-will-be-fully-allocated-to-reduce-2025-senior-secured-notes-and-2027-term-loan-b-and-on-a-pro-rata-basis-as-per-credit-agreement-to-repay-in-full-2025-debt-maturities-leaving-no-additional-maturities-until-2027

- Reuters 

 grifols-subsidiary-biotest-receives-fda-approval-for-yimmugo-an-intravenous-immunoglobulin-therapeutic-to-treat-primary-immunodeficiencies-with-us-launch-expected-in-second-part-of-2024

With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to m...

 grifols-chairman-glanzmann-says-cfo-alfredo-arroyo-to-step-down-role-of-grifols-chairman-will-no-longer-be-executive

- Bloomberg

 grifols-q1-net-revenues-163-billion-vs-156-billion-yoy-sees-q1-rd-negative-net-investment-905-million-vs-1047-million-yoy-currently-working-to-improve-fcf-guidance-in-light-of-several-ongoing-initiatives-to-hold-investor--analysts-day-on-oct-10

- Reuters 

 grifols-on-track-to-meet-fy-guidance-and-reduce-debt

- Reuters

 grifols-achieves-results-from-phase-4-study-of-fanhdi-in-patients-with-von-willebrand-disease

https://www.grifols.com/en/view-news/-/news/grifols-achieves-positive-results-from-phase-4-study-of-fanhdi-double-inactivated-h...

 carmax-reports-downbeat-earnings-joins-lovesac-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday.